Key Highlights

  • Surgery Partners (NASDAQ:SGRY) soared 47.62% on October 26, 2026 after an affiliate of Bon Secours Mercy Health agreed to acquire the company for USD 23.50 a share in cash, according to a company 8-K.
  • The transaction values Surgery Partners at an enterprise value of about USD 5.7 billion, which includes debt, and the company release did not disclose the premium or the equity value.
  • Bain Capital, which holds about 39% of the shares, will roll its stake into the new structure instead of selling, and the companies expect closing in the first quarter of 2027.
  • The cash bid confirms last week's take-private report and supersedes the earlier media figure of about USD 20 a share, which is roughly 17.5% below the agreed price in simple arithmetic.

What Was Agreed

Surgery Partners announced on October 26, 2026 that an affiliate of Bon Secours Mercy Health will buy the company for USD 23.50 a share in cash. The enterprise value of about USD 5.7 billion combines the equity price with the company's net debt. The company release did not state a premium to the prior close or the total equity value, so those must be calculated from market prices after the merger documents are filed. Closing is expected in the first quarter of 2027. The announcement confirmed a take-private report from the previous week, and it replaces the earlier media figure of about USD 20 a share, which proved too low. A merger agreement of this kind normally includes a go-shop or no-shop clause that decides whether the board may seek better offers, and the proxy statement will describe it.

How a Rolled Stake and an All-Cash Bid Work

In an all-cash acquisition, shareholders receive a fixed price instead of shares in the buyer, so the stock trades near the offer price less a discount for the time and risk until closing. That discount is the merger spread. Bain Capital's roughly 39% holding will roll into the new ownership structure, which means the largest holder is staying invested and not cashing out, a signal of continued confidence but also a sign that the other holders' vote matters less. The affiliate of a non-profit health system buying an operator of surgical facilities is an unusual pairing that regulators may examine closely. Shareholders other than Bain Capital would vote on the transaction, and a fall in the vote count would change the outlook.

Risks and What to Watch

The main risks are regulatory approval, financing, shareholder approval and the first quarter of 2027 timetable. If approvals fail or are delayed, the shares could fall back toward their pre-deal level. Investors will watch the proxy statement for the background of the sale, other bidders, and the board's fairness opinion. After a 47.62% one-day jump the shares will trade as a bond-like claim on the USD 23.50 price, so further upside is limited unless a competing bid appears. Nothing here is investment advice. Regulators may look at overlaps in surgical facilities and physician relationships. Lenders also matter, because a buyout of this size usually relies on committed financing that must stay in place until closing. If the shares trade at a wide discount to USD 23.50, that discount would signal that investors doubt completion.

Where Things Stand

The answer is that Surgery Partners (NASDAQ:SGRY) soared 47.62% because the market moved from a rumour of about USD 20 to a confirmed USD 23.50 cash offer, with an enterprise value of about USD 5.7 billion and Bain Capital rolling its roughly 39% stake. The premium and equity value were not disclosed. Approvals and financing are the main hurdles before the expected first quarter of 2027 close. The proxy statement will show the sale process in detail.